Drugs / ZFN2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02695160 | Nov 2016 → Apr 2021 | hemophilia B | Sangamo Therapeutics | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03041324 | May 2017 → May 2021 | mucopolysaccharidosis type 2 | Sangamo Therapeutics | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZFN2 | “Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.” NCT02695160 ↗1“Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor” NCT03041324 ↗ |